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Introduction
Treatment switching in clinical trials dilutes estimates of
treatment effect which is problematic in decision mak-
ing, especially in an economic context. In one example
75% of patients crossover from the randomised treat-
ment which emphasises the need to address such bias.
We consider methodologies that compensate for this
bias.
Methods
The methods assessed are; intention to treat (ITT), per-
protocol (PP), adjusted Cox model [1], causal propor-
tional hazards estimator [2], rank-preserving structural
failure-time models (RPSFT) [3], iterative parameter
estimation (IPE) [4], parametric randomisation based
method [5], and the less well known inverse probability
of treatment weighting (IPTW) [6].
Data
Survival data having an underlying Weibull distribution
was simulated and designed such that probability of
switching for patient subgroups could be varied within
treatment-arms. Other subgroup characteristics could be
controlled and 24 scenarios with varied levels of bias
were analysed. A review of submissions to the National
Institute of Clinical Excellence was performed and used
to inform the scenario parameters.
Results
The RPSFT and IPE methods returned the lowest biases,
<8%, in all scenarios. The estimates of the parametric
randomisation based method were often far less variable
than other methods but were subject to erratic beha-
viour with extreme biases observed. The other methods
performed poorly in general, with biases of up to 50%
not uncommon. In particular the IPTW method over-
compensates in most scenarios.
Conclusion
Under these conditions the results clearly identified the
RPSFT and IPE methods as most consistent and accu-
rate, with the latter the more consistent of the two.
None of the other methods retu r n e dc o n s i s t e n tr e s u l t s ,
and as such cannot be recommended.
Further avenues of investigation include exploring the
effect of other underlying survival distributions, extend-
ing from univariate models to adjust for other covari-
ates, and extending from situations where just control-
arm patients switch to scenarios with multidirectional
cross-over.
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